Stockreport

Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight [Yahoo! Finance]

Neurocrine Biosciences, Inc.  (NBIX) 
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: neurocrine.com/about-us/webcasts-presentations
PDF In the 7MM, the US accounted for the highest prevalent cases of congenital adrenal hyperplasia in 2023, with around of the total prevalent cases across the 7MM; these n [Read more]